Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry

P. G. Gibson*, H. Reddel, V. M. McDonald, G. Marks, C. Jenkins, A. Gillman, J. Upham, M. Sutherland, J. Rimmer, F. Thien, G. P. Katsoulotos, M. Cook, I. Yang, C. Katelaris, S. Bowler, D. Langton, P. Robinson, C. Wright, V. Yozghatlian, S. BurgessP. Sivakumaran, A. Jaffe, J. Bowden, P. A.B. Wark, K. Y. Yan, V. Kritikos, M. Peters, M. Hew, A. Aminazad, M. Bint, M. Guo

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

68 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry'. Together they form a unique fingerprint.

Immunology and Microbiology